Maria Scatolini

Experienced Head of Laboratory with a demonstrated history of working in Research and Molecular Diagnostic field. Skilled in Molecular Oncology, Cancer Genomics. Excellent reputation for team leadership, problem solving and public speaking. Strong healthcare services professional with a Medical Specialty focused in Clinical Pathology and a PhD in Human Oncology.

• Head, Molecular Oncology Laboratory, Fondazione Edo ed Elvo Tempia ONLUS, via dei Ponderanesi 2, Ponderano, BI, 13875, Italy, 10/01/11, present, Management and coordination of personnel involved in molecular diagnostics and oncology research activities in solid tumors., Responsibility for clinical reporting of molecular tests., Implementation of new methods and markers in clinical practice., Evaluation of clinically relevant markers through various sequencing and analysis methods., Design and participation in grant applications., Participation and coordination of European tenders in molecular diagnostics., Participation in advisory board and consultation activities for the pharmaceutical industry., Quality Manager for the Laboratory.
• Technical Inspector (Accredia), Accredia, 09/01/21, present, Evaluate Medical Laboratories in compliance with UNI EN ISO 15189:2023 scheme.
• Researcher, Cancer Genomic Laboratory, Fondazione Edo ed Elvo Tempia, via Malta 3, Biella, 13900, Italy, 10/01/08, 09/30/11
• PhD student, in Human Oncology, Cancer Genomic Laboratory, Fondazione Edo ed Elvo Tempia, via Malta 3, Biella, 13900, Italy, 11/01/05, 09/30/08

• Registered with the National Order of Biologists (Section A, No. AA_070931)
• Member of the Technical Commission for the NGS Network supporting the Healthcare and Social-Healthcare Services Planning Sector of the Piedmont Region
• Member of SIGU (Italian Society of Human Genetics)
• Coordinator of the Molecular Pathology Study Group for the Oncology Network of Piedmont and Aosta Valley
• Member of the MTB (Molecular Tumor Board) of the Oncology Network of Piedmont and Aosta Valley

• CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential, Deaglio S, Vaisitti T, Aydin S, Bergui L, D’Arena G, Bonello L, Omede’ P, Scatolini M, Jaksic O, Chiorino G, Efremov D, Malavasi F, Blood, 12/01/07, 110, 12, 4012-21
• From single gene to integrative molecular concept maps: pitfalls and potentials of the technology of microarray, Chiorino G., Mello Grand M., Scatolini M. and Ostano P., J Biol Regul Homeost Agents, 01/03/08, 22, 1, 7-16
• In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation, Venesio T, Chiorino G, Balsamo A, Zaccagna A, Petti C, Scatolini M, Pisacane A, Sarotto I, Picciotto F and Risio M., Mod Pathol, 06/01/08, 21, 6, 716-26
• Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity, Brusa D, Garetto S, Chiorino G, Scatolini M, Migliore E, Camussi G, Matera L., Vaccine, 11/25/08, 26, 50, 6422-32
• The epithelial-mesenchymal transition induced by keratinocyte growth conditions is overcome by E6 and E7 from HPV16, but not HPV8 and HPV38: characterization of global transcription profiles., Azzimonti B, Dell'oste V, Borgogna C, Mondini M, Gugliesi F, De Andrea M, Chiorino G, Scatolini M, Ghimenti C, Landolfo S, Gariglio M., Virology, 06/05/09, 388, 2, 260-9
• Altered molecular pathways in melanocytic lesions., Scatolini M, Mello Grand M, Grosso E, Venesio T, Pisacane A, Balsamo A, Sirovich R, Risio M, Chiorino G., Int J Cancer, 04/15/10, 126, 8, 1869-81
• Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer., Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G., Breast Cancer Res Treat, 06/01/10, 121, 2, 399-411
• Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells, Cutrupi S, Reineri S, Panetto A, Grosso E, Caizzi L, Ricci L, Friard O, Agati S, Scatolini M, Chiorino G, Lykkesfeldt AE, De Bortoli M., Oncogene, 10/04/12, 31, 40, 4353-61
• Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions., Maldi E, Travelli C, Caldarelli A, Agazzone N, Cintura S, Galli U, Scatolini M, Ostano P, Miglino B, Chiorino G, Boldorini R, Genazzani AA., Pigment Cell Melanoma Res, 01/01/13, 26, 1, 144-6
• Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy., Ghimenti C, Mello-Grand M, Grosso E, Scatolini M, Regolo L, Zambelli A, Chiorino G., Exp Ther Med, 03/01/13, 5, 3, 902-906
• P63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis., Matin RN, Chikh A, Law Pak Chong S, Mesher D, Graf M, Sanza’ P, Senatore V, Scatolini M, Moretti F, Leigh IM, Proby CM, Costanzo A, Chiorino G, Cerio R, Harwood CA, Bergamaschi D., J Exp Med, 03/11/13, 210, 3, 581-603
• Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2., Borsotti P, Ghilardi C, Ostano P, Silini A, Dossi R, Pinessi D, Foglieni C, Scatolini M, Lacal PM, Ferrari R, Moscatelli D, Sangalli F, D'Atri S, Giavazzi R, Bani MR, Chiorino G, Taraboletti G., Pigment Cell Melanoma Res, 01/01/15, 28, 1, 73-81
• Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer., Lefort K, Ostano P, Mello-Grand M, Calpini V, Scatolini M, Farsetti A, Dotto GP, Chiorino G., Oncotarget, 07/26/16, 7, 30, 48011-48026
• Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma., Benfodda M, Gazal S, Descamps V, Basset-Seguin N, Deschamps L, Thomas L, Saiag P, Zanetti R, Sacchetto L, Chiorino G, Scatolini M, Grandchamp B, Soufir N., Genes Chromosomes Cancer, 06/01/18, 57, 6, 294-303
• Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients., Peraldo-Neia C
• Scatolini M
• Grosso E, Lombardi P, Filippi R, Raggi C, Marchiò C, Cavalloni G, Aglietta M, Leone F., Cancers (Basel), 03/30/19, 11, 4
• Targeting p63 upregulation abrogates resistance to MAPK inhibitors in melanoma., Patel A, Fraile Garcia L, Mannella V, Gammon L, Borg TM, Maffucci T, Scatolini M, Chiorino G, Vergani E, Rodolfo M, Maurichi A, Posch C, Matin RN, Harwood CA, Bergamaschi D., Cancer Res, 06/15/20, 80, 12, 2676-2688
• Molecular Characterization and clinical correlation of papillary thyroid microcarcinoma., Samà MT, Grosso E, Mele C, Laurora S, Monzeglio, Marzullo P, Boldorini R, Aluffi Valletti P, Aimaretti G, Scatolini M, Pagano L., Endocrine, 07/03/20
• Malignant struma ovarii: next generation sequencing of six cases revealed NRAS, BRAF and JAK3 mutations., Poli R, Scatolini M, Grosso E, Maletta F, Gallo M, Liscia D, Nelva A, Cesario F, Forte G, Metovic J, Volante M, Arvat Emanuela M, Papotti M., Endocrine, 08/02/20
• GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma., Scatolini M, Patel A, Grosso E, Mello-Grand M, Ostano P, Coppo R, Vitiello M, Venesio T, Zaccagna A, Pisacane A, Sarotto I, Taverna D, Poliseno L, Bergamaschi D, Chiorino G., Br J Dermatol, 07/08/21
• Ribociclib Cytotoxicity Alone Or Combined With Progesterone And/Or Mitotane In In Vitro Adrenocortical Carcinoma Cells., Abate A, Rossini E, Tamburello M, Laganà M, Cosentini D, Grisanti S, Fiorentini C, Tiberio GAM, Scatolini M, Grosso E, Hantel C, Memo M, Berruti A, Sigala S., Endocrinology, 12/07/21
• Biomarker characterization in endometrial cancer in Italy: first survey data analysis., Gian Franco Zannoni et al… (Scatolini M)., Pathologica, 06/01/22, 114, 3, 189-198
• Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles., Akhouayri L, Ostano P, Mello-Grand M, Gregnanin I, Crivelli F, Laurora S, Liscia D, Leone F, Santoro A, Mulè A, Guarino D, Maggiore C, Carlino A, Magno S, Scatolini M, Di Leone A, Masetti R, Chiorino G., Hum Genomics, 12/20/22, 16, 1, 70
• Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs., Santoro A, Bragantini E, Castiglione F, Ganesan R, Matias-Guiu X, Frattini M, Gallotta V, Garcia P, Pattni Y, Tsiampali-Laprell J, Bisaro B, Barbareschi M, Zannoni GF; Collaborators (Scatolini M) (IT ESP UK, CH)., Pathologica, 02/01/24, 116, 1, 32-45
• Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience., Pepe F et al (Scatolini M)., Oncol Ther, 03/01/24, 12, 1, 73-95
• Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma., M Scatolini, S Grisanti, P Tomaiuolo, E Grosso, V Basile, D Cosentini, S Puglisi, M Laganà, P Perotti, L Saba, E Rossini, F Palermo, S Sigala, M Volante, A Berruti, M Terzolo., Eur J Cancer, 04/26/24, 205, 114088

• ID Number: SCTMRA81A65A859D
• Date of Birth: 01/25/81
• Nationality: Italian

• Registered in the Regional Order of Biologists (Section A, No. AA_070931)
• Member of the Technical Commission for the NGS Network supporting the Healthcare and Social-Healthcare Services Planning Sector of the Piedmont Region
• Member of SIGU (Italian Society of Human Genetics)
• Coordinator of the Molecular Pathology Study Group for the Oncology Network of Piedmont and Aosta Valley
• Member of the MTB (Molecular Tumor Board) of the Oncology Network of Piedmont and Aosta Valley